- Home
- GMRS vs ALLO Comparison
GMRS vs ALLO Comparison
Compare GMRS & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GMRS | ALLO |
|---|---|---|
| Founded | 2018 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 551.0M | 452.6M |
| IPO Year | 2026 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GMRS | ALLO |
|---|---|---|
| Price | $11.17 | $1.18 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 12 |
| Target Price | ★ $18.63 | $9.00 |
| AVG Volume (30 Days) | 726.6K | ★ 6.7M |
| Earning Date | 11-09-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.09 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.13 | N/A |
| Revenue Next Year | $5.57 | $216.23 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.00 | $1.04 |
| 52 Week High | $15.98 | $4.46 |
Technical Indicators
Market Signals| Indicator | GMRS | ALLO |
|---|---|---|
| Relative Strength Index (RSI) | 55.70 | 29.18 |
| Support Level | $9.75 | N/A |
| Resistance Level | $14.14 | $2.22 |
| Average True Range (ATR) | 0.51 | 0.09 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 74.45 | 4.30 |
Price Performance
Historical ComparisonAbout GMRS GMR Solutions Inc. Class A Common Stock
GMR Solutions Inc is a holding company, along with its various subsidiaries, that delivers compassionate, quality medical care, meeting a patient's unplanned and planned care needs. The group provides emergent, non-emergent, disaster response, and event medical services across the healthcare ecosystem, serving local communities, health systems, payors, public health, and local, state, and federal agencies within the United States.
About ALLO Allogene Therapeutics Inc.
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).